Brian Powl
Corporate Officer/Principal en KURA ONCOLOGY, INC. .
Fortuna: 621 962 $ al 31/03/2024
Perfil
Brian T.
Powl is currently the Chief Commercial Officer at Kura Oncology, Inc. He previously worked as the Vice President-Global Commercial CAR T Lead at Celgene Corp., Senior VP-Commercial Development & Marketing at MEI Pharma, Inc., and Chief Commercial Officer at Fate Therapeutics, Inc. Powl received his undergraduate degree from the University of California San Diego and his MBA from The Wharton School of the University of Pennsylvania.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
KURA ONCOLOGY, INC.
0.02% | 02/01/2024 | 15 000 ( 0.02% ) | 319 950 $ | 31/03/2024 |
FATE THERAPEUTICS, INC.
0.04% | 05/07/2023 | 41 146 ( 0.04% ) | 302 012 $ | 31/03/2024 |
Cargos activos de Brian Powl
| Empresas | Cargo | Inicio |
|---|---|---|
| KURA ONCOLOGY, INC. | Corporate Officer/Principal | 14/08/2023 |
Antiguos cargos conocidos de Brian Powl.
| Empresas | Cargo | Fin |
|---|---|---|
| CELGENE | Corporate Officer/Principal | - |
| FATE THERAPEUTICS, INC. | Corporate Officer/Principal | - |
| MEI PHARMA, INC. | Sales & Marketing | - |
Formación de Brian Powl.
| University of California San Diego | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| KURA ONCOLOGY, INC. | Health Technology |
| MEI PHARMA, INC. | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
- Bolsa de valores
- Insiders
- Brian Powl
